| Project/Area Number |
26461959
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
Tetsu Hayashida 慶應義塾大学, 医学部(信濃町), 講師 (80327543)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
神野 浩光 帝京大学, 医学部, 教授 (20216261)
高橋 麻衣子 慶應義塾大学, 医学部(信濃町), 助教 (50348661)
|
|---|
| Project Period (FY) |
2014-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 乳癌 / ベバシズマブ / 血管新生 / HOXB9 / 乳がん |
|---|
| Outline of Final Research Achievements |
Homeobox B9 (HOXB9), a transcriptional factor, regulates developmental processes and tumor progression and has recently been recognized as a strong angiogenic factor in breast cancer progresson. This study aimed to investigate the role of HOXB9 in tumorigenesis and angiogenesis. Bevacizumab, an anti-VEGF antibody, remarkably suppressed tumor proliferation by inhibiting angiogenesis in HOXB9-overexpressing xenografts. HOXB9 promotes the secretion of angiogenic factors, including VEGF, to induce tumor proliferation through microenvironmental communication via IL6 signaling; moreover, silencing of VEGF or IL6 terminates microenvironmental crosstalk. Thus, HOXB9 and IL6 may be surrogate markers for bevacizumab treatment in breast cancer.
|
